Ink (she/her). INTJ. Late 20s. Writer, mostly for Star Wars: The Clone Wars. (Requests are currently closed.) Find past works on my Masterlist! Want to be tagged in future works? Sign up on my Taglist Form! Enjoy what I do? Here's a link to my Ko-Fi!
Hey, friends! This is my main blog. It was where I originally shared my writing, but I have switched to using a writing side-blog because the taglist ended up being too much to handle.
I have left my masterlist and the original fics up here. However, my new writing has moved to @wanderinginksplot-writes. The masterlist there is updated, whereas the one here only shows fics up to the point that I created the side-blog.
My spicy works are over on @somedaylazysomeday. 18+ only, please!
This blog is shifting to more of a reblog-heavy, multi-fandom collection of everything I like. You are more than welcome to follow me here (I do reblog my work from the side-blog), but I also swear and occasionally reblog spicy things, so this is not strictly a minor-friendly space.
For ease of access, here are the links to my (un-updated) masterlist
Here is my desktop masterlist.
Here is my mobile masterlist.
Here is the updated masterlist on the writing side-blog.
This has been in my drafts for two full years because I wanted to say something deep and insightful about how Star Wars: Rebels managed to accidentally create one of the most realistic enemies-to-lovers arcs I've seen in modern media.
But in the end, my experience boils down to two distinct bullet points.
Me watching early Rebels after seeing MANY posts about Kallus and Zeb: "Hmm. I don't really see any chemistry between them, but Tumblr is the Make It Gay website, so I see how we ended up here."
Me watching The Honorable Ones: "Oh, these two are in love. How did I miss it before?"
For millions of people managing type 2 diabetes, mornings begin the same way — a needle, a dose, and a quiet mental note to do it all again
"For millions of people managing type 2 diabetes, mornings begin the same way — a needle, a dose, and a quiet mental note to do it all again tomorrow.
That routine just changed.
On March 26, 2026, the U.S. Food and Drug Administration approved Awiqli (insulin icodec-abae), developed by Novo Nordisk, as the first and only once-weekly basal insulin ever approved for adults with type 2 diabetes in the United States.
This is not a minor update to an existing drug.
It is the first entirely new class of basal insulin to reach U.S. patients in more than two decades.
Instead of injecting insulin every single day, people with type 2 diabetes using Awiqli will only need one shot per week, on the same day, every week.
That means reducing from 365 injections a year down to just 52.
For anyone who has ever felt the weight of that daily ritual — the anxiety of forgetting, the physical discomfort, the constant reminder that their body needs help — this approval represents something much bigger than a dosing schedule.
It represents relief.
How the Drug Actually Works
Understanding why this injection lasts a full week requires a quick look inside the body.
Most traditional basal insulins are absorbed into the bloodstream and begin breaking down within 24 hours, which is why patients need a fresh dose every day to maintain stable blood sugar levels.
Awiqli works differently.
Its active ingredient, insulin icodec-abae, is engineered to loosely attach to a blood protein called albumin, which is found naturally and abundantly in the bloodstream.
This attachment creates a slow-release reservoir.
Instead of flooding the system and fading fast, the insulin releases gradually and consistently over an entire seven-day period, keeping blood sugar in a healthy range around the clock...
The FDA reviewed and ultimately declined to approve it for people with type 1 diabetes, citing concerns about a modestly increased risk of hypoglycemia in that population specifically.
Some regulatory agencies in other countries, including the European Union, Canada, Australia, and Japan, have approved Awiqli for both type 1 and type 2 diabetes, but for now the U.S. approval is limited to type 2...
What Comes Next
Awiqli is not standing alone in this space for long.
Eli Lilly is developing its own once-weekly basal insulin, called efsitora alfa, which is currently in late-stage clinical trials.
If that drug also earns FDA approval, it would give patients and doctors two once-weekly options to choose from, allowing for personalized decisions based on a patient’s health profile, insurance coverage, and individual response.
The broader direction of travel in diabetes care is unmistakable.
Fewer injections, smarter formulations, and better integration with digital tools like continuous glucose monitors and insulin-tracking apps are all converging toward a future where managing diabetes requires less daily mental effort without becoming any less medically precise...
A Small Shot With Large Implications
It is easy to look at a once-weekly injection and see only a scheduling change.
But the science behind Awiqli, the scale of the ONWARDS trials, and the consistent satisfaction reported by patients all point toward something that matters far more than convenience.
Diabetes management has always asked a lot of people.
It asks for daily vigilance, daily discipline, and a daily willingness to confront one’s own condition, sometimes in uncomfortable or inconvenient circumstances.
Anything that reduces that load, without reducing the quality of care, is worth taking seriously.
For the more than 37 million Americans living with diabetes, and the hundreds of millions more around the world, a simpler weekly routine could mean the difference between a treatment plan that works on paper and one that actually works in a person’s life.
That is the real significance of what the FDA approved on March 26, 2026.
Not just a new drug.
A new way of keeping people healthy, one week at a time."
